{"id":151121,"date":"2023-08-03T09:57:52","date_gmt":"2023-08-03T13:57:52","guid":{"rendered":"https:\/\/44.250.171.167\/?p=151121"},"modified":"2023-08-03T09:57:53","modified_gmt":"2023-08-03T13:57:53","slug":"supriya-lifescience-ltd-q1fy24-16-rise-in-profits","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/supriya-lifescience-ltd-q1fy24-16-rise-in-profits\/","title":{"rendered":"Supriya Lifescience Ltd Q1FY24; 16% rise in Profits"},"content":{"rendered":"\n<p>Supriya Lifescience is engaged in the manufacturing of Active pharmaceutical ingredients (APIs). As of March 31, 2021, the company produces 38 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and anti-allergic.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Financial Results:<\/h2>\n\n\n\n<p>Supriya Lifescience Ltd reported Revenues for Q1FY24 of \u20b9132.00 Crores up from \u20b9101.00 Crore year on year, a rise of 30.69%.<\/p>\n\n\n\n<p>Total Expenses for Q1FY24 of \u20b993.00 Crores up from \u20b974.00 Crores year on year, a rise of 25.68%.<\/p>\n\n\n\n<p>Consolidated Net Profit of \u20b929.00 Crores up 16.0% from \u20b925.00 Crores in the same quarter of the previous year.<\/p>\n\n\n\n<p>The Earnings per Share is \u20b93.54, up 12.74% from \u20b93.14 in the same quarter of the previous year.<\/p>\n\n\n\n<div class=\"wp-block-image\"><figure class=\"aligncenter size-large\"><a href=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-150.png\"><img loading=\"lazy\" decoding=\"async\" width=\"839\" height=\"1024\" src=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-150-839x1024.png\" alt=\"\" class=\"wp-image-151122\" srcset=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-150-839x1024.png 839w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-150-246x300.png 246w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-150-768x937.png 768w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-150-1259x1536.png 1259w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-150.png 1489w\" sizes=\"auto, (max-width: 839px) 100vw, 839px\" \/><\/a><\/figure><\/div>\n\n\n\n<p>*It is important to note that the way the results have been accounted for are slightly different than the ones the companies may choose to publish.<\/p>\n\n\n\n<p>*The presented data is automatically generated. It may occasionally generate incorrect information.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Supriya Lifescience is engaged in the manufacturing of Active pharmaceutical ingredients (APIs). As of March 31, 2021, the company produces 38 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and anti-allergic. Financial Results: Supriya Lifescience Ltd reported Revenues for Q1FY24 of \u20b9132.00 Crores up from \u20b9101.00 Crore year on year, [&hellip;]<\/p>\n","protected":false},"author":1863,"featured_media":151122,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[105,392,5747],"tags":[10304,12577,1115],"class_list":["post-151121","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-infographics","category-earnings","category-healthcare-stocks","tag-api","tag-lifescience","tag-pharmaceuticals"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-150.png","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":164722,"url":"https:\/\/alphastreet.com\/india\/supriya-lifescience-ltd-q1fy24-16-rise-in-profits-2\/","url_meta":{"origin":151121,"position":0},"title":"Supriya Lifescience Ltd Q1FY24; 16% rise in Profits","author":"Chirag Gupta","date":"October 7, 2024","format":false,"excerpt":"Supriya Lifescience is engaged in the manufacturing of Active pharmaceutical ingredients (APIs). As of March 31, 2021, the company produces 38 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and anti-allergic. Financial Results: Supriya Lifescience Ltd reported Revenues for Q1FY24 of \u20b9132.00 Crores up from\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/10\/image-36.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/10\/image-36.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/10\/image-36.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/10\/image-36.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/10\/image-36.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/10\/image-36.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":155892,"url":"https:\/\/alphastreet.com\/india\/supriya-lifescience-ltd-q2fy24-41-rise-in-profits\/","url_meta":{"origin":151121,"position":1},"title":"Supriya Lifescience Ltd Q2FY24; 41% rise in Profits","author":"Chirag Gupta","date":"November 7, 2023","format":false,"excerpt":"Supriya Lifescience is engaged in the manufacturing of Active pharmaceutical ingredients (APIs). As of March 31, 2021, the company produces 38 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and anti-allergic. Financial Results: Supriya Lifescience Ltd reported Revenues for Q2FY24 of \u20b9140.00 Crores up from\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/11\/image-93.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/11\/image-93.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/11\/image-93.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/11\/image-93.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/11\/image-93.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/11\/image-93.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":153733,"url":"https:\/\/alphastreet.com\/india\/nectar-lifescience-ltd-q1fy24-53-fall-in-profits\/","url_meta":{"origin":151121,"position":2},"title":"Nectar Lifescience Ltd Q1FY24; 53% fall in Profits","author":"Karan_Singh","date":"August 14, 2023","format":false,"excerpt":"Nectar Lifesciences Ltd is primarily engaged in the development, manufacture and marketing of various active pharmaceutical ingredients (APIs) and finished dosage forms. Financial Results: Nectar Lifescience Ltd reported Revenues for Q1FY24 of \u20b9394.13 Crores down from \u20b9403.03 Crore year on year, a fall of 2.21%. Total Expenses for Q1FY24 of\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-1018.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-1018.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-1018.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-1018.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-1018.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/08\/image-1018.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":170225,"url":"https:\/\/alphastreet.com\/india\/supriya-lifescience-q1-fy26-earnings-results\/","url_meta":{"origin":151121,"position":3},"title":"Supriya Lifescience Q1 FY26 Earnings Results\u00a0","author":"Chirag Gupta","date":"August 15, 2025","format":false,"excerpt":"Supriya Lifescience is engaged in the manufacturing of Active pharmaceutical ingredients (APIs). As of March 31, 2021, the company produces 38 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and anti-allergic. Syntec Do Brasil LTDA, American International Chemical Inc. and AT Planejamento E Desenvolvimento De\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Supriya Lifescience Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/4-10.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/4-10.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/4-10.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/4-10.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/4-10.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/08\/4-10.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":133424,"url":"https:\/\/alphastreet.com\/india\/supriya-lifescience-ltd-q1-fy23-earnings-conference-call-insights\/","url_meta":{"origin":151121,"position":4},"title":"Supriya Lifescience Ltd Q1 FY23 Earnings Conference Call Insights","author":"Praveen","date":"August 23, 2022","format":false,"excerpt":"https:\/\/youtu.be\/LNBcyeiXX0U Key highlights from Supriya Lifescience Ltd (SUPRIYA) Q1 FY23 Earnings Concall Management Update: SUPRIYA said the company is extending its backward integration model to its new products to maintain the competitive edge. The company added that a larger part of the growth and sustainability will be driven by the\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":129979,"url":"https:\/\/alphastreet.com\/india\/supriya-lifescience-ltd-q4-fy22-earnings-conference-call-insights\/","url_meta":{"origin":151121,"position":5},"title":"Supriya Lifescience Ltd Q4 FY22 Earnings Conference Call Insights","author":"Praveen","date":"May 24, 2022","format":false,"excerpt":"https:\/\/youtu.be\/VIL70Aj2g04 Key highlights from Supriya Lifescience Ltd (SUPRIYA) Q4 FY22 Earnings Concall Management Update: SUPRIYA said that going forward the company\u2019s focus would be on improving its infrastructure, which includes debottlenecking of its capacity and developing new manufacturing blocks. Q&A Highlights: Naresh Vaswani of Sameeksha Capital asked about the reason\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/151121","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1863"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=151121"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/151121\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/151122"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=151121"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=151121"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=151121"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}